Femasys Inc 8-K, filed Sep 20, 2021
Femasys Inc (FEMY)
8-K
2021-09-20
For: 2021-09-20
View Original
Added on
April 06, 2026
About this 8-K
Femasys Inc filed this 8-K on September 20, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 20, 2021
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(770 ) 500-3910
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instructions A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 8.01 |
Other Events.
|
On September 20, 2021, Femasys Inc. (the “Company”) announced that it has been added
to the Russell Microcap® Index effective today when the U.S. market opened. A
copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
No.
|
Description
|
|
Press Release of Femasys Inc. dated September 20, 2021.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Femasys Inc.
|
||
|
By:
|
/s/ Kathy Lee-Sepsick
|
|
|
Names: Kathy Lee-Sepsick
|
||
|
Title: Chief Executive Officer
|
||
Date: September 20, 2021
Exhibit 99.1
ATLANTA, September 20, 2021 -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to
transform women’s healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell
Microcap® Index today when the U.S. market opened. The Russell Microcap Index is widely used by
investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
"We are thrilled to be included in the Russell Microcap Index following our IPO in June since it benefits both our Company and
stockholders by accentuating our visibility within the global investment community,” commented president, chief executive officer and founder of Femasys, Kathy Lee-Sepsick. “We believe that our inclusion reflects executing on a strong business
model, offering differentiated and dramatically improved options to address unmet areas of women’s health, and, additionally, underscores our goal to transform the standard-of-care for women globally in these underserved areas. We look forward
to creating value for our stockholders with upcoming catalysts for our late-stage product candidates. We expect to complete enrollment for our FemBloc® stage II validation study before the end of this year and conduct our FemaSeed™
interim analysis the first half of next year – both products, if brought to market, have the potential to markedly transform the landscape of women’s healthcare,” Ms. Lee-Sepsick added.
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and
value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9
trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs,
structured products, and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information on the Russell Microcap® Index and the Russell indexes reconstitution, please
visit www.ftserussell.com.
About FemaSeed™
FemaSeed is a directed sperm delivery product in development for infertility. FemaSeed is the first and only approach that allows localized directed delivery of
sperm to either or both fallopian tubes where conception occurs. FemaSeed is being evaluated in a prospective, multi-center pivotal trial, the “LOCAL” trial.
About FemBloc®
FemBloc is a first and only non-surgical, minimally invasive, in-office solution for permanent birth control in development. FemBloc uses a temporary degradable
biopolymer that is naturally excreted to close the fallopian tubes using the body’s own scar tissue. FemBloc is currently being evaluated in a prospective, multi-center stage II validation study.
About Femasys
Femasys Inc. is a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office
technologies. Its two lead reproductive health product candidates include FemBloc® permanent birth control and FemaSeed™ localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCerv®, a technology platform for tissue
sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements
can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “believe,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual
results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others:
our ability to develop and advance our current product candidates and programs into, and successfully initiate and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and
other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and
uncertainties described in the section titled "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2021, and other reports as filed with the SEC. Forward-looking statements
contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com